105192-42-5

Basic information

• Product Name: Methanone, (2-amino-5-chlorophenyl)-4-pyridinyl-
• CAS NO: 105192-42-5
• Molecular Formula: C12H9ClN2O
• Molecular Weight: 232.669
• Mol File: 105192-42-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Methanone, (2-amino-5-chlorophenyl)-4-pyridinyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanone, (2-amino-5-chlorophenyl)-4-pyridinyl-(105192-42-5)
• EPA Substance Registry System: Methanone, (2-amino-5-chlorophenyl)-4-pyridinyl-(105192-42-5)

Safety Data

• Hazardous Substances Data: 105192-42-5(Hazardous Substances Data)

Upstream product

• 106-47-8 4-chloro-aniline 
• 55-22-1 pyridine-4-carboxylic acid 
• 52482-36-7 morpholin-4-yl(pyridin-4-yl)methanone 
• 65854-91-3 N-(4-chlorophenyl)-2,2-dimethylpropionamide 
• 628300-66-3 N-[4-chloro-2-(pyridine-4-carbonyl)phenyl]-2,2-dimethylpropionamide 
• 100-48-1 pyridine-4-carbonitrile 
• 872-85-5 pyridine-4-carbaldehyde 

Downstream Products

• 133069-27-9 C₁₆H₁₃ClN₆O₃ 
• 133031-95-5 C₃₄H₂₈ClN₄O₃P 
• 698394-73-9 N-{4-chloro-2-[(1-oxidopyridin-4-yl)carbonyl]phenyl}-4-(1,1-dimethylethyl) benzenesulfonamide 
• 628300-71-0 N-{4-chloro-2-[(1-oxidopyridin-4-yl)carbonyl]phenyl}-4-(propan-2-yloxy)benzenesulfonamide 
• 698394-72-8 4-tert-butyl-N-[4-chloro-2-(pyridine-4-carbonyl)-phenyl]-benzenesulfonamide 
• 133031-87-5 C₁₆H₁₃Cl₂N₃O₃ 

Relevant articles and documents

PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME

The present invention provides a prophylactic or therapeutic agent and a prophylactic or therapeutic method superior in the prophylaxis or treatment of Sjogren's syndrome. Provided are a prophylactic or therapeutic agent for Sjogren's syndrome, containing

COMPOUNDS WHICH INCREASE APOLIPOPROTEIN A-1 PRODUCTION AND USES THEREOF IN MEDICINE

The present invention relates to compounds of formula (I), pharmaceutically acceptable salts thereof, hydrates thereof, solvates thereof, prodrugs thereof and combinations thereof: wherein X represents CH or N; Y represents CH or N; R1 represents H or C1-2alkyl; R2 represents H or C1-4alkyl; R3 represents C1-6alkyl, carbocyclyl, carbocyclylC1-4alkyl, heterocyclyl or heterocyclylC1-4alkyl, wherein any of the carbocyclyl or heterocyclyl groups are optionally substituted by one or two groups selected from: halogen, C1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, nitro, cyano, -COH, -COOH, C1-6alkoxycarbonyl, C1-6alkylcarbonyl, -C(OH)R5R6 (wherein R5 and R6 independently represent H or C1-6alkyl), -(CH2)nNR3aR3b and -O(CH2)pNR3aR3b (wherein n represents 1, 2 or 3, p represents 2 or 3 and R3a and R3b independently represent H, C1-6alkyl or carbocyclylC1-4alkyl, or R3a and R3b together with the interconnecting atoms form a 5 or 6-membered ring which ring optionally contains one or two heteroatoms independently selected from the group consisting of O, S and N); R4 represents H, hydroxy, halo, C 1-6 alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, C2-6alkenyl, C1-6alkoxy, haloC1-6alkoxy, carbocyclyl or heterocyclyl, wherein the carbocyclyl or heterocyclyl group is optionally substituted by one or two groups selected from: halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, nitro and cyano; and provided that the compound is not: 7-chloro-5-phenyl-[1,2,4]triazolo[4,3-a]quinolin-4-amine; 7-chloro-1-methyl-5-phenyl[1,2,4]triazolo[4,3-a]quinolin-4-amine; or 7-chloro-5-(2-chlorophenyl)-1-methyl-{1,2,4]triazolo[4,3-a]quinolin-4-amine. Also disclosed are pharmaceutical compositions containing the compounds and to their use in medicine. The compound exhibit increased apo-A1 production and are useful in the treatment for example a disease or condition caused by raised levels of LDL-cholesterol or by inflammation.

ARYL SULFONAMIDES

Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.